EBGI Category: IBD
-
SEAVUE: A Sea of Change in Biologic Positioning for Crohn’s Disease
American College of Gastroenterology / EBGI Articles / IBD / SEAVUE: A Sea of Change in Biologic Positioning for Crohn’s DiseaseSEAVUE: A Sea of Change in Biologic Positioning for Crohn’s Disease Bharati Kochar, MD, MS Division of Gastroenterology, Massachusetts General…
-
ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCT
American College of Gastroenterology / EBGI Articles / IBD / ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCTIn Case You Missed It Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis: The…
-
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
American College of Gastroenterology / EBGI Articles / IBD / Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF TherapyACG EBGI: This Evidence-based summary looks at D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials. Lancet 2022;399(10340):2015-30.
-
Subcutaneous risankizumab is effective and safe for the maintenance of moderate-to-severe Crohn’s disease
American College of Gastroenterology / EBGI Articles / IBD / Subcutaneous risankizumab is effective and safe for the maintenance of moderate-to-severe Crohn’s diseaseACG EBGI: Evidence-based summary reviews Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal Phase 3 FORTIFY maintenance trial. Lancet 2022;399(10340):2031-2046.
-
Ozanimod for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UC
American College of Gastroenterology / EBGI Articles / IBD / Ozanimod for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UCOzanimod for Moderate-Severe Ulcerative Colitis: Rethinking the Top-Down Treatment Algorithm Oriana Damas, MD1 and Philip Schoenfeld, MD, MSEd, MSc (Epi)2…
-
Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes
American College of Gastroenterology / EBGI Articles / IBD / Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal OutcomesContinuing Anti-TNF Agents Past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes…
-
NSAID Use and the Risk of IBD Exacerbations: Fact or Fiction
American College of Gastroenterology / EBGI Articles / IBD / NSAID Use and the Risk of IBD Exacerbations: Fact or FictionNSAID Use and the Risk of IBD Exacerbations: Fact or Fiction? Philip N. Okafor, MD, MPH1 1Senior Associate Consultant, Department…
-
Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UC
American College of Gastroenterology / EBGI Articles / IBD / Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UCUpadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for Ulcerative Colitis Jami Kinnucan, MD1…
-
Continue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes Pregnant
American College of Gastroenterology / EBGI Articles / IBD / Continue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes PregnantContinue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes Pregnant: Results from the Pregnancy in IBD and Neonatal Outcomes…
-
Achieve IBD Remission Before Pregnancy
Achieve IBD Remission Before Pregnancy: PIANO Registry Data Shows Adverse Perinatal Outcomes For Infants Associated with IBD Flares and Steroid…